Disease · MONDO_0005148
Comparisons in its trials1,032
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 1,032
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Aims 1, 2B, and 3 Groups vs Aim 2A Group: deaths from any cause | 22,208 of 386,276 | 0 of 25 | 386,301 | NCT05214573 | Trial comparisons |
| Aims 1, 2B, and 3 Groups vs Aim 2A Group: serious adverse events | 40,642 of 386,276 | 0 of 25 | 386,301 | NCT05214573 | Trial comparisons |
| SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause | 1,371 of 163,812 | 2,524 of 163,812 | 327,624 | NCT03817463 | Trial comparisons |
| Empagliflozin Initiators vs Dipeptidyl Peptidate-4 Inhibitor (DPP4i) Initiators: deaths from any cause | 341 of 20,279 | 1,528 of 41,918 | 62,197 | NCT05465317 | Trial comparisons |
| Type 1 Diabetes vs Type 2 Diabetes: serious adverse events | 130 of 13,529 | 80 of 37,641 | 51,170 | NCT00659295 | Trial comparisons |
| Empagliflozin - PS Balanced Cohort vs Liraglutide - PS Balanced Cohort: deaths from any cause | 881 of 14,148 | 765 of 12,626 | 26,774 | NCT03993132 | Trial comparisons |
| Insulin Degludec vs Insulin Glargine: Occurrence of at Least One EAC Confirmed Severe Hypoglycaemic Episode Within a Subject (Yes/no) | 187 of 3,818 | 252 of 3,819 | 7,637 | NCT01959529 | Trial comparisons |
| Insulin Degludec vs Insulin Glargine: serious adverse events | 1,473 of 3,818 | 1,517 of 3,819 | 7,637 | NCT01959529 | Trial comparisons |
| Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death. | 350 of 3,686 | 395 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: All-cause Hospitalization | 1,573 of 3,686 | 1,605 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: deaths from any cause | 339 of 3,686 | 383 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: All-cause Mortality | 333 of 3,686 | 370 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death | 108 of 3,686 | 139 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure. | 458 of 3,686 | 519 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: serious adverse events | 1,158 of 3,683 | 1,215 of 3,658 | 7,341 | NCT02545049 | Trial comparisons |
| Linagliptin vs Glimepiride: deaths from any cause | 308 of 3,023 | 336 of 3,010 | 6,033 | NCT01243424 | Trial comparisons |
| Linagliptin vs Glimepiride: serious adverse events | 1,403 of 3,023 | 1,448 of 3,010 | 6,033 | NCT01243424 | Trial comparisons |
| Finerenone vs Placebo: All-cause Mortality | 219 of 2,833 | 244 of 2,841 | 5,674 | NCT02540993 | Trial comparisons |
| Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death | 504 of 2,833 | 600 of 2,841 | 5,674 | NCT02540993 | Trial comparisons |
| Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, or Hospitalization for Heart Failure | 367 of 2,833 | 420 of 2,841 | 5,674 | NCT02540993 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005148/comparisons